Deficit Reduction

Showing 817 articles
Business

Merck Navigates Mixed Q4 2025 with Oncology Strength Offsetting Vaccine Slump, Sets Cautious 2026 Outlook

Merck & Co. reported a 5% rise in Q4 2025 revenue to $16.4 billion, powered by its blockbuster cancer drug Keytruda and animal health division. However, a steep 35% drop in Gardasil sales, attributed to weakened demand in Asia, highlighted regional vulnerabilities. The pharmaceutical giant issued initial 2026 guidance projecting modest growth while absorbing a significant one-time charge from its recent Cidara Therapeutics acquisition.

Business

Naked Wines Shows Signs of a Turnaround as Capital Efficiency Improves

The online wine retailer, Naked Wines, is demonstrating a notable shift in its financial performance. While its overall return on capital remains modest, recent trends indicate the company is generating higher returns from a significantly reduced capital base—a potential sign of improving operational efficiency and strategic asset management.

Business

Waymo Secures $16B at $126B Valuation, Navigating Growth Amid Safety Scrutiny

The autonomous vehicle leader Waymo has catapulted to a $126 billion valuation after a massive $16 billion funding round, marking its transition from a moonshot project to a commercial-scale operation. Yet, this financial milestone arrives as the company faces intensified regulatory pressure following a series of incidents involving its robotaxis and school buses.